Elanco Animal Health Incorporated (NYSE:ELAN) Holdings Lowered by Country Club Bank

Country Club Bank cut its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 1.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,073 shares of the company’s stock after selling 2,364 shares during the period. Country Club Bank’s holdings in Elanco Animal Health were worth $1,561,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Jennison Associates LLC boosted its stake in Elanco Animal Health by 1.4% during the 4th quarter. Jennison Associates LLC now owns 1,095,710 shares of the company’s stock valued at $13,269,000 after purchasing an additional 15,246 shares in the last quarter. Spire Wealth Management boosted its stake in Elanco Animal Health by 107.4% during the fourth quarter. Spire Wealth Management now owns 7,776 shares of the company’s stock valued at $94,000 after buying an additional 4,026 shares in the last quarter. Institute for Wealth Management LLC. grew its holdings in Elanco Animal Health by 11.5% during the fourth quarter. Institute for Wealth Management LLC. now owns 35,516 shares of the company’s stock worth $430,000 after acquiring an additional 3,656 shares during the period. KBC Group NV raised its position in Elanco Animal Health by 264.9% in the fourth quarter. KBC Group NV now owns 323,502 shares of the company’s stock worth $3,918,000 after acquiring an additional 234,840 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in Elanco Animal Health by 66.7% in the 4th quarter. Blue Trust Inc. now owns 6,615 shares of the company’s stock valued at $80,000 after acquiring an additional 2,647 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ELAN. Barclays lifted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Morgan Stanley cut their price objective on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 29th. Leerink Partners assumed coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price on the stock. Finally, UBS Group assumed coverage on Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 target price for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Elanco Animal Health presently has a consensus rating of “Hold” and an average target price of $16.29.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $12.03 on Thursday. The company has a market capitalization of $5.94 billion, a price-to-earnings ratio of 30.06, a P/E/G ratio of 2.71 and a beta of 1.42. Elanco Animal Health Incorporated has a 1-year low of $11.11 and a 1-year high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock’s fifty day simple moving average is $12.10 and its 200-day simple moving average is $13.22.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.01. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business’s revenue for the quarter was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.18 EPS. On average, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.